Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.24 | N/A | +12.73% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.24 | N/A | +12.73% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to advancing their drug development pipeline.
Management did not provide specific revenue figures for the quarter.
The company is focused on its ongoing projects and pipeline development.
BioCryst Pharmaceuticals reported a loss per share that was better than expected, but the lack of revenue details may have raised concerns among investors. The stock fell nearly 5% in response, reflecting uncertainty about the company's financial health and future performance. Investors will be looking for more clarity in upcoming reports.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARATHON PETE CORP
Aug 3, 2020